PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing improved biotherapeutics for the treatment of orphan diseases, with an initial focus on cardiopulmonary disorders.

Our proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which may lead to less-frequent dosing and better patient compliance.

PB1046, or lead development candidate, is a vasoactive intestinal peptide (VIP) receptor agonist that leverages our ELP technology for once-weekly dosing. PB1046 is being evaluated in clinical trials in pulmonary arterial hypertension and in preclinical studies for the treatment of cardiomyopathy associated with dystrophinopathies. PhaseBio recently concluded a Phase 2a trial of PB1046 in patients with heart failure with reduced ejection fraction.

We are also evaluating our development candidate PB2452, a reversal agent for the antiplatelet therapy ticagrelor, in clinical trials. PB2452 was exclusively licensed from MedImmune, the global biologics research and development arm of AstraZeneca, for global development and commercialization by PhaseBio.

PhaseBio continues to explore opportunities to apply our ELP biopolymer technology to compounds that may benefit from its unique properties. We are privately owned, with headquarters and research laboratories in Malvern, PA.